Lilly revisits Alzheimer’s drug
July 15, 2013Research and Development, Sales and Marketing Alzheimer's, lilly, solanezumab
Eli Lilly & Co is to run yet another trial of its Alzheimer’s drug solanezumab, which failed twice in Phase …
Roche’s Erivedge gains conditional EU approval
July 15, 2013Sales and Marketing Curis, EU, Erivedge, Roche, Swiss, Zelboraf
Roche’s cancer pill Erivedge has received a conditional European approval for treatment of the most common type of skin cancer. …
Next generation digital firms for Europe wanted
July 15, 2013Medical Communications, Sales and Marketing J&J, JJ, digital, innovation
Digital health start-ups from across Europe are being called on to form a part of Johnson & Johnson Innovation’s inaugural …
Simon Lowth exits AstraZeneca
July 15, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, simon lowth
AstraZeneca’s chief financial officer and executive director Simon Lowth will leave the firm at the end of October. Lowth has …
FDA approves Boehringer’s lung cancer drug
July 12, 2013Medical Communications, Sales and Marketing Boehringer, FDA, Roche, Tarceva, afatinib, lung cancer
Boehringer Ingelheim’s late-stage lung cancer drug Gilotrif has received an accelerated FDA approval for patients with a certain genetic mutation. …
UK science future looking brighter – survey
July 12, 2013Research and Development, Sales and Marketing UCB, science
A new survey undertaken by UCB has found that enthusiasm for science in the UK is high, but adds that …
Eliquis poised for new US approval
July 12, 2013Sales and Marketing BMS, Bayer, DVT, Eliquis, warfarin
Pfizer and Bristol-Myers Squibb have submitted their oral direct Factor Xa inhibitor Eliquis to the FDA to prevent deep vein …
Eisai backs disease fund
July 12, 2013Research and Development, Sales and Marketing Eisai, Japan, TB, partnership
A leading Japanese pharma group says that the sector should see investment in fighting diseases of the developing world as …
China accuses GSK of large scale bribery
July 12, 2013Medical Communications, Research and Development, Sales and Marketing Avandia, China, GSK, Seroxat
Health officials in China say they have found evidence GSK tried to generate sales and raise drug prices by bribing …
Publicis Life Brands Resolute appoints account director
July 12, 2013Medical Communications, Sales and Marketing PLBR
Publicis Life Brands Resolute (PLBR) has hired Simon Goldsborough as an account director. Goldsborough brings to the firm over 10 …
MHRA orders recall of Wockhardt drugs after import ban
July 11, 2013Manufacturing and Production MHRA, Wockhardt, recall
The UK regulatory authority has asked for a recall of medicines made at a Wockhardt facility in India, shortly after …
Amgen signs Servier deal
July 11, 2013Sales and Marketing Amgen, Servier, heart, procoloran
Amgen has gained rights in the US to two of Servier’s heart drugs: the novel, oral Procoralan and investigational Phase …
AstraZeneca shores up Cambridge move
July 11, 2013Research and Development, Sales and Marketing AstraZeneca, Cambridge, research and development
AstraZeneca has cemented its position in Cambridge, the UK location of its purpose-built global HQ from 2016, by signing deals …
Tissue Regenix
 appoints non-executive director
July 11, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing tissue regenix
Regenerative medical devices firm Tissue Regenix has appointed Randeep Singh Grewal as its non-executive
 director of the Group. Grewal has …
NICE no for Celgene’s Revlimid
July 11, 2013Sales and Marketing Celgene, NICE, Revlimid
NICE has issued new draft guidance not recommending Celgene’s bone marrow disorder drug Revlimid over uncertainties of its efficacy. Revlimid …
Pharma chooses Microsoft in drug counterfeit fight
July 10, 2013Medical Communications, Sales and Marketing Microsoft, azure, windows
Microsoft’s Azure cloud platform has been selected to power the new EU-wide European Medicines Verification System (EMVS) that will be …
Blow for Roche as it halts diabetes drug trial
July 10, 2013Research and Development, Sales and Marketing Roche, aleglitazar, diabetes
Roche has stopped a late-stage trial of its investigational diabetes drug aleglitazar over safety concerns. The move was prompted by …
Court overturns orphan refusal
July 10, 2013Sales and Marketing EMA, laboratoires ctrs, orphacol
A European Commission decision last year to refuse marketing authorisation for an orphan drug has been overturned by a major …
Fresenius Kabi hit by second FDA warning letter
July 10, 2013Manufacturing and Production API, FDA, Fresenius Kabi, GMP
German generic drugmaker Fresenius Kabi has been sent another warning letter from the FDA citing deficiencies at a manufacturing plant. …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
